View Item 

Show simple item record

Evaluating the severity of dermatologic disorders

dc.contributor.authorGrekin, Sarah J.en_US
dc.contributor.authorEllis, Charles N.en_US
dc.date.accessioned2010-06-01T18:31:26Z
dc.date.available2010-06-01T18:31:26Z
dc.date.issued2009-05en_US
dc.identifier.citationGrekin, Sarah J.; Ellis, Charles N. (2009). "Evaluating the severity of dermatologic disorders." Dermatologic Therapy 22(3): 191-198. <http://hdl.handle.net/2027.42/71730>en_US
dc.identifier.issn1396-0296en_US
dc.identifier.issn1529-8019en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71730
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19453342&dopt=citationen_US
dc.description.abstractAssessment of a patient's disease severity is an essential component of formulating therapeutic strategies. However, disorders of the skin are often not amenable to strict classification criteria, and the dermatologist relies upon personal thresholds of severity when assessing the patient's overall condition. A number of grading systems have arisen, primarily from the need for standardized end points in clinical trials; in some circumstances, these severity assessments may assist the clinician in the evaluation and treatment of dermatologic disease. In this review, we will summarize the results of available severity scores of frequently encountered dermatologic disorders and discuss their utility in the management of disease in a clinician's office.en_US
dc.format.extent234432 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2009 Wiley Periodicals, Inc.en_US
dc.subject.otherDisease Severityen_US
dc.subject.otherQuality of Lifeen_US
dc.subject.otherSkin Diseaseen_US
dc.titleEvaluating the severity of dermatologic disordersen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid19453342en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71730/1/j.1529-8019.2009.01231.x.pdf
dc.identifier.doi10.1111/j.1529-8019.2009.01231.xen_US
dc.identifier.sourceDermatologic Therapyen_US
dc.identifier.citedreferenceRees JL. Trials, evidence, and the management of patients with psoriasis. J Am Acad Dermatol 2003: 48: 135 – 143.en_US
dc.identifier.citedreferenceChren MM. Giving “scale” new meaning in dermatology: measurement matters. Arch Dermatol 2000: 136: 788 – 790.en_US
dc.identifier.citedreferenceBellamy N. Science of assessment. Ann Rheum Dis 2005: 64 (Suppl. 2 ): ii42 – ii45.en_US
dc.identifier.citedreferenceKrueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001: 137: 280 – 284.en_US
dc.identifier.citedreferenceFeldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol 2005: 53: 101 – 107.en_US
dc.identifier.citedreferenceFeldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005: 64 ( Suppl. 2 ): ii65 – ii68.en_US
dc.identifier.citedreferenceFredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978: 157: 238 – 244.en_US
dc.identifier.citedreferenceBerth-Jones J, Thompson J, Papp K, Copenhagen Psoriasis Working Group. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008: 159: 407 – 412.en_US
dc.identifier.citedreferenceMease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006: 54: 685 – 704.en_US
dc.identifier.citedreference10.  European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. 2004. http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf/. Accessed November 3, 2008.en_US
dc.identifier.citedreferenceLangley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004: 51: 563 – 569.en_US
dc.identifier.citedreferenceBerth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006: 155: 707 – 713.en_US
dc.identifier.citedreferenceNaldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977–2000: The EDEN survey. J Invest Dermatol 2003: 120: 738 – 741.en_US
dc.identifier.citedreferenceCharman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000: 136: 763 – 769.en_US
dc.identifier.citedreferenceGelmetti C, Colonna C. The value of SCORAD and beyond. Towards a standardized evaluation of severity? Allergy 2004: 59 (Suppl. 78 ): 61 – 65.en_US
dc.identifier.citedreferenceOranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek, FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007: 157: 645 – 648.en_US
dc.identifier.citedreferenceHanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M, EASI evaluator group. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001: 10: 11 – 18.en_US
dc.identifier.citedreferencePicardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006: 54: 420 – 426.en_US
dc.identifier.citedreferenceAlosh M, Wilkin J. Assessing the relationship between Investigator Global Evaluation and acne lesion counts. Drug Information Journal 2004: 38: 343 – 351.en_US
dc.identifier.citedreferenceGoulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999: 41: 577 – 580.en_US
dc.identifier.citedreferenceHayashi N, Akamatsu H, Kawashima M, Acne Study Group. Establishment of grading criteria for acne severity. J Dermatol 2008: 35: 255 – 260.en_US
dc.identifier.citedreferenceDreno B, Khammari A, Orain N, et al. ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology. Dermatology 2007: 214: 46 – 51.en_US
dc.identifier.citedreferenceOlsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines – Part II. J Am Acad Dermatol 2004: 51: 440 – 447.en_US
dc.identifier.citedreferenceStrutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004: 51: 241 – 248.en_US
dc.identifier.citedreferenceSolish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007: 33: 908 – 923.en_US
dc.identifier.citedreferenceGriffiths CE, Wang TS, Hamilton TA, Voorhees JJ, Ellis CN. A photonumeric scale for the assessment of cutaneous photodamage. Arch Dermatol 1992: 128: 347 – 351.en_US
dc.identifier.citedreferenceKirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001: 45: 72 – 76.en_US
dc.identifier.citedreferenceSalek S, Roberts A, Finlay AY. The practical reality of using a patient-reported outcome measure in a routine dermatology clinic. Dermatology 2007: 215: 315 – 319.en_US
dc.identifier.citedreference29.  US Department of Health and Human Services Food and Drug Administration. Guidance for Industry – Patient-reported outcome measures: use in medical product development to support labeling claims [Draft, 2006 ]. http://www.fda.gov/cder/guidance/5460dft.pdf. Accessed December 3, 2008.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1529-8019.2009.01231.x.pdf
Size:
228.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.